ArticleCancers2021

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).

Marta Padovan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.